Article

PDT + triamcinolone shows promise as treatment for non-subfoveal CNV

Short-term results from a small study suggest combined verteporfin (Visudyne,Novartis) photodynamic therapy (PDT) with intravitreal triamcinolone meritsadditional investigation for the treatment of non-subfoveal CNV, said RichardF. Spaide, MD.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Survey reveals gaps in patient awareness of preservative-free glaucoma treatments
March 14th 2025

Survey reveals gaps in patient awareness of preservative-free glaucoma treatments

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension
March 13th 2025

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Choroidal vascularity index offers insight into eye health after COVID-19 recovery
March 12th 2025

Choroidal vascularity index offers insight into eye health after COVID-19 recovery

FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

© 2025 MJH Life Sciences

All rights reserved.